Sabatino Susan A, Thompson Trevor D, Croswell Jennifer M, Villarroel Maria A, Rodriguez Juan L, Adam Emily E, Richardson Lisa C
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy, Mailstop S107-4, Atlanta, GA 30341-3717 (
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Prev Chronic Dis. 2025 Aug 14;22:E52. doi: 10.5888/pcd22.250139.
The objective of this analysis was to provide national estimates for use of breast, cervical, and colorectal cancer (CRC) screening tests, including for the recently expanded CRC screening age group (ages 45-75 y).
We used data from the 2023 National Health Interview Survey to estimate proportions of screening-eligible adults up to date with breast (women aged 50-74 y), cervical (women aged 21-65 y), and CRC screening (adults aged 45-75 y). We compared breast and CRC estimates age-standardized to the 2000 US standard population to Healthy People 2030 (HP2030) targets. Age-standardized estimates of breast, cervical, and CRC test use were compared with estimates from 2019 (breast, cervical) and 2021 (breast, cervical, CRC).
In 2023, estimated percentages of adults up to date were 80.0% (95% CI, 78.7%-81.2%), 75.4% (95% CI, 74.1%-76.6%), and 67.4% (95% CI, 66.3%-68.4%), for breast, cervical, and CRC screening test use, respectively. CRC test use was lower among those aged 45 to 49 years than those aged 50 to 75 years (37.1% vs 73.4%, P < .001). Mammography use approximated the HP2030 target. CRC test use was below the target. Breast, cervical, and CRC screening test use varied with almost all sociodemographic characteristics and health care access, financial hardship, and other barriers examined. Mammography estimates were somewhat higher and cervical test estimates were lower in 2023 than in 2019 and 2021. CRC test use was lower in 2023 than 2021.
In 2023, most adults were up to date with breast, cervical, and CRC screening test use; however, 1 in 3 adults (CRC) to 1 in 5 adults (breast) were not. Future monitoring can help determine if changes continue and track progress toward national targets.
本分析的目的是提供全国范围内乳腺癌、宫颈癌和结直肠癌（CRC）筛查检测的使用情况估计，包括最近扩大的CRC筛查年龄组（45至75岁）。
我们使用了2023年全国健康访谈调查的数据，以估计符合筛查条件的成年人中进行乳腺癌（50至74岁女性）、宫颈癌（21至65岁女性）和CRC筛查（45至75岁成年人）的比例。我们将根据2000年美国标准人群进行年龄标准化的乳腺癌和CRC估计值与《健康人民2030》（HP2030）目标进行比较。将乳腺癌、宫颈癌和CRC检测使用的年龄标准化估计值与2019年（乳腺癌、宫颈癌）和202
